Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor (Q38073160)

28 August 2017

1 reference

title

Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor (English)

1 reference

28 August 2017

Emanuele Barbato

2

0 references

William Wijns

object named as

William Wijns

series ordinal

5

0 references

Marc Vanderheyden

series ordinal

4

object named as

Marc Vanderheyden

1 reference

28 August 2017

1

Jozef Bartunek

1 reference

28 August 2017

3

Guy Heyndrickx

1 reference

28 August 2017

6

Josefin-Beate Holz

1 reference

PubMed ID

23307200

28 August 2017

language of work or name

English

0 references

publication date

11 January 2013

1 reference

Journal of Cardiovascular Translational Research

28 August 2017

1 reference

28 August 2017

6

1 reference

28 August 2017

355-363

1 reference

28 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s12265-012-9435-y

28 August 2017

0 references

cites work

Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Scientific and therapeutic advances in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Antiplatelet therapy: in search of the 'magic bullet'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Acute coronary syndromes: Diagnosis and management, part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Acute coronary syndromes: diagnosis and management, part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Percutaneous coronary intervention for chronic stable angina: a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Antiplatelet drugs: how to select them and possibilities of combined treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Platelet receptors and signaling in the dynamics of thrombus formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-012-9435-Y

Contemporary use of glycoprotein IIb/IIIa inhibitors

21 January 2018

1 reference

12 December 2020

Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

1 reference

12 December 2020

Novel therapies in the pipeline: Directions of research into platelet inhibition

1 reference

12 December 2020

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis

1 reference

12 December 2020

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

1 reference

12 December 2020

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

1 reference

12 December 2020

Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs

1 reference

12 December 2020

von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina

1 reference

12 December 2020

The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura

1 reference

12 December 2020

Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates

1 reference

12 December 2020

The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.

1 reference

12 December 2020

10.1007/S12265-012-9435-Y

Identifiers

DOI

1 reference

PubMed ID

23307200

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23307200